Venus Medtech (Hangzhou) Management
Management criteria checks 1/4
Venus Medtech (Hangzhou)'s CEO is Lin Haosheng Lim, appointed in Nov 2023, has a tenure of 1.5 years. total yearly compensation is CN¥2.79M, comprised of 97% salary and 3% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth HK$3.08K. The average tenure of the management team and the board of directors is 3.2 years and 2.3 years respectively.
Key information
Lin Haosheng Lim
Chief executive officer
CN¥2.8m
Total compensation
| CEO salary percentage | 96.95% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.0003% |
| Management average tenure | 3.2yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?
Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?
May 29What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You
May 11Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook
Apr 07Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?
Oct 12Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates
Sep 04We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate
Jul 28Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth
Mar 29Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?
Jan 09Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation
Dec 01We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow
Aug 16A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)
Jul 12Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth
Apr 26Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%
Apr 05Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate
Mar 07What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?
Feb 14
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner
Jan 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥3m | CN¥3m | -CN¥714m |
| Sep 30 2024 | n/a | n/a | -CN¥637m |
| Jun 30 2024 | n/a | n/a | -CN¥560m |
| Mar 31 2024 | n/a | n/a | -CN¥632m |
| Dec 31 2023 | CN¥264k | CN¥223k | -CN¥704m |
| Sep 30 2023 | n/a | n/a | -CN¥956m |
| Jun 30 2023 | n/a | n/a | -CN¥1b |
| Mar 31 2023 | n/a | n/a | -CN¥1b |
| Dec 31 2022 | CN¥1m | CN¥1m | -CN¥1b |
| Sep 30 2022 | n/a | n/a | -CN¥759m |
| Jun 30 2022 | n/a | n/a | -CN¥461m |
| Mar 31 2022 | n/a | n/a | -CN¥417m |
| Dec 31 2021 | CN¥1m | CN¥694k | -CN¥374m |
Compensation vs Market: Lin Haosheng's total compensation ($USD388.54K) is above average for companies of similar size in the Hong Kong market ($USD229.60K).
Compensation vs Earnings: Lin Haosheng's compensation has increased whilst the company is unprofitable.
CEO
Lin Haosheng Lim (49 yo)
Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Executive Director at Ve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 1.5yrs | CN¥2.79m | 0.00027% HK$ 3.1k | |
| VP & Executive Director | 2.3yrs | CN¥1.75m | no data | |
| VP of clinical medicine & Executive Director | 1.4yrs | CN¥1.93m | 0.0084% HK$ 95.8k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Director of Sales | 3.2yrs | no data | no data | |
| Head of U.S. Operations | 5.8yrs | no data | no data | |
| Head of Venus Global Heart Valve Innovation Center | 3.2yrs | no data | no data | |
| Head of International Congenital Heart Disease Business | 3.2yrs | no data | no data | |
| Company Secretary | 4.3yrs | no data | no data |
Experienced Management: 2500's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 1.4yrs | CN¥2.79m | 0.00027% HK$ 3.1k | |
| VP & Executive Director | 2.3yrs | CN¥1.75m | no data | |
| VP of clinical medicine & Executive Director | 1.4yrs | CN¥1.93m | 0.0084% HK$ 95.8k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Global Advisory Board | 5.3yrs | no data | no data | |
| Independent Chairman of the Board | 6.5yrs | CN¥420.00k | no data | |
| Independent Non-Executive Director | 5.8yrs | CN¥420.00k | no data | |
| Non-Executive Director | 1.5yrs | no data | no data | |
| Member of Global Advisory Board | 5.3yrs | no data | no data | |
| Non-Executive Director | 2.3yrs | no data | no data | |
| Employee Representative Chairman of the Supervisory Committee | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | CN¥33.00k | 0.13% HK$ 1.4m |
Experienced Board: 2500's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 18:13 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Venus Medtech (Hangzhou) Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Haoyuan Zhang | China Merchants Securities (HK) Co., Ltd |